Lixte (United States)

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

Jie Lu, John S. Kovach, Francis Johnson et al. · Proceedings of the National Academy of Sciences · 2009 · 161 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Vincent Chung, Aaron S. Mansfield, Fadi Braiteh et al. · Clinical Cancer Research · 2016 · 126 citations

Pharmacy, Oncology, Pharmacology +9

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Winson S. Ho, Herui Wang, Dominic Maggio et al. · Nature Communications · 2018 · 91 citations · Full text

Life Sciences, Immunology, Oncology +17

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

Matheus Henrique Dias, Anoek Friskes, Siying Wang et al. · Cancer Discovery · 2024 · 50 citations · Full text

Medicine, Cancer Biology, Oncology +17

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma

Jing Cui, Herui Wang, Rogelio Medina et al. · Cancers · 2020 · 47 citations · Full text

Medicine, Immunology, Oncology +17